January 18, 2019
AgeneBio starts enrolling patients in third phase of testing cognitive impairment do to AD
AgeneBio has enrolled its first out of 830 patient in a Phase 3 clinical trial of its investigational medication AGB101, to treat amnestic Mild Cognitive Impairment due to Alzheimer’s Disease (MCI due to AD).